Inhalation of alendronate nanoparticles as dry powder inhaler for the treatment of osteoporosis

Journal of Microencapsulation

Volumn 29, Issue 5, 2012, Pages 445-454

  Sultana, Shaheen ^a   Talegaonkar, Sushma ^a   Ali, Rashid ^b   Mittal, Gaurav ^b   Ahmad, Farhan Jalees ^a   Bhatnagar, Aseem ^b  

^a HAMDARD UNIVERSITY   (India)

^b INSTITUTE OF NUCLEAR MEDICINE AND ALLIED SCIENCES   (India)

Author keywords

central composite design; lutrol; precipitation; stabilizers

Indexed keywords

ALENDRONIC ACID; ALGINIC ACID; CHITOSAN; NANOPARTICLE; SURFACTANT;

ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; OSTEOPOROSIS; PARTICLE SIZE; POWDER INHALER; VALIDATION STUDY;

ADMINISTRATION, INHALATION; ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; CHEMICAL PRECIPITATION; DRUG CARRIERS; DRY POWDER INHALERS; EXCIPIENTS; HUMANS; LUNG; NANOPARTICLES; OSTEOPOROSIS; PARTICLE SIZE; POLOXAMER; SURFACE-ACTIVE AGENTS;

EID: 84863809115     PISSN: 02652048     EISSN: 14645246     Source Type: Journal    
DOI: 10.3109/02652048.2012.655428     Document Type: Article

References (40)

1. Biradar SV, Patil AR, Sudarsan GV, Pokharkar VB. A comparative study of approaches used to improve solubility of roxithromycin. Powder Technol, 2006;169(24):22-32.
2. Bosquillon C, Lombry C, Preat V, Vanbever R. Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerolization performance. J Control Rel, 2001;70:329-39.
3. Chesnut CH, Skag A, Christiansen C. Oral ibandronate osteoporosis vertebral fracture trial in North America and Europe (BONE). Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res, 2004;19:1241-9.
4. Chow AHL, Tong HHY, Chattopadhyay P, Shekunov BY. Particle engineering for pulmonary drug delivery. Pharm Res, 2007;24(3):411-37.
5. Coates MS, Chan HK, Fletcher DF, Chiou H. Influence of mouthpiece geometry on the aerosol delivery performance of a dry powder inhaler. Pharm Res, 2007;24(8):1450-6.
6. Conte P, Guarneri V. Safety of Intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist, 2004;9(4):28-37.
7. Cruz L, Fattal E, Tasso L, Freitas GC, Carregaro AB, Guterres SS, Pohlmann AR, Tsapis N. Formulation and in vivo evaluation of sodium alendronate spray-dried microparticles intended for lung delivery. J Control Release, 2011;152(3):370-5.
8. Dai WG, Dong LC, Song WQ. Nanosizing of a drug/carrageenan complex to increase solubility and dissolution rate. Int J Pharm, 2007;342:201-7.
9. Dalvi SV, khopadhyay M. A novel process for precipitation of ultra-fine particles using sub-critical CO2. Powder Tech, 2009;195(3):190-5.
10. Dong Y, Ng WK, Shen S, Kim S, Tan Reginald BH. Preparation and characterization of spironolactone nanoparticles by antisolvent precipitation. Int J Pharm, 2009;375:84-8.
11. Fakes MG, Vakkalagadda BJ, Qian F, Desikan S, Gandhi RB, Lai C, Hsieh A, Franchini MK, Toale HBJ. Enhancement of oral bioavailability of an HIVattachment inhibitor by nanosizing and amorphous formulation approaches. Int J Pharm, 2009;370:167-74.
12. Finlay WH. 2001. Mechanics of inhaled pharmaceutical aerosols: An introduction. New York: Academic Press.
13. Gao L, Zhang D, Chen M, Duan C, Dai W, Jia L, Zhao W. Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions. Int J Pharm, 2008;355:321-7.
14. Garcia-Contreras L, Hickey AJ. Pharmaceutical and biotechnological aerosols for cystic fibrosis therapy. Adv Drug Delivery Rev, 2002;54:1491-504.
15. Grenha A, Seijo B, Remunán-López C. Microencapsulated chitosan nanoparticles for lung protein delivery. Eur J Pharm Sci, 2005;25:427-37.
16. Hardy JG, Chadawick TS. Sustained release drug delivery to the lungs. Clin Pharmacokinet, 2000;39:1-4.
17. Hartwig S, Heike GB. A novel spray-drying technique to produce low density particles for pulmonary delivery. Int J Pharm, 2004;278:187-95.
18. Hezave AZ, Esmaeilzadeh F. Micronization of drug particles via RESS proces. J Supercrit Fluids, 2010;52(1):84-98.
19. Katsumi H, Takashima M, Sano J, Nishiyama K, Kitamura N, Sakane T, Hibi T, Yamamoto A. Development of polyethylene glycol-conjugated alendronate, a novel nitrogen-containing bisphosphonate derivative: Evaluation of absorption, safety, and effects after intrapulmonary administration in rats. J Pharm Sci, 2011;100(9):3783-92.
20. Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: Physiological factors affecting therapeutic effectiveness of aerosolized medications. J Clin Pharmacol, 2003;56:588-99.
21. Lee J, Lee SJ, Choi JY, Yoo JY, Ahn CH. Amphiphilic amino acid copolymers as stabilizers for the preparation of nanocrystal dispersion. Eur J Pharm Sci, 2005;24(5):441-9.
22. Lenth RV. Response-surface methods in R, using RSM. J Stat Software, 2009;32(7):1-17.
23. Lin SY, Kawashima Y. The influence of three poly (-oxtethylene) poly (oxypropylene), surface-active block copolymers on the solubility behavior of indomethacin. Pharm Acta Helv, 1985;60:339-44.
24. Lou H, Zhang X, Gao L, Feng F, Wang J, Wei X, Yu Z, Zhang D, Zhang Q. In vitro and in vivo antitumor activity of oridonin nanosuspension. Int J Pharm, 2009;379:181-6.
25. Malcolmson RJ, Embleton JK. Dry powder formulations for pulmonary delivery. Pharm Sci Technol, 1998;1(9):394-8.
26. Mauludin R, Müller RH, Keck CM. Development of an oral rutin nanocrystal formulation. Int J Pharm, 2009;370:202-9.
27. Meyers RH, Montgomery DC. 2002. Response surface methodology. 2nd ed. New York: Wiley-Interscience
28. Newman SP, Busse WW. Evolution of dry powder inhaler design, formulation, and performance. Respir Med, 2002;96:293-304.
29. Niwa T, Shimabara H, Kondo M, Danjo K. Design of porous microparticles with single-micron size by novel spray freeze-drying technique using four-fluid nozzle. Int J Pharm, 2009;382:88-97.
30. Pandey R, Khuller GK. Antitubercular inhaled therapy: Opportunities, progress and challenges. J Antimicrob Chemother, 2005;55:430-5.
31. Rao R, Markovic S, Anderson P. Aerosol therapy for malignancy involving the lungs. Curr Cancer Drug Targets, 2003;3:239-50.
32. Rogueda PG.A.,Traini D. The nanoscale in pulmonary delivery: Part 1 rogueda pga traini d the nanoscale in pulmonary delivery: Part 1deposition, fate, toxicology and effects. Expert Opin Drug Discovery, 2007;4(6):595-606.
33. Russell RGG. Bisphosphonates: Mode of action and pharmacology. Pediatrics, 2007;119:S150-62.
34. Sham JO, Zhang Y, Finlay WH, Roa WH, Raimar L. Formulation and characterization of spray dried powders containing nanoparticles for aerosol delivery to the lung. Int J Pharm, 2004;269:457-67.
35. Sharma P, Denny WA, Garg S. Effect of wet milling process on the solid state of indomethacin and simvastatin. Int J Pharm, 2009;380:40-8.
36. Tozuka Y, Miyazaki Y, Takeuchi H. A combinational supercritical CO2 system for nanoparticle preparation of indomethacin. Int J Pharm, 2010;386:243-8.
37. Verma S, Gokhale R, Burgess DJ. A comparative study of top-down and bottom-up approaches for the preparation of micro/nanosuspensions. Int J Pharm, 2009a;380:216-22.
38. Verma S, Lan Y, Gokhale R, Burgess DJ. Quality by design approach to understand the process of nanosuspension preparation. Int J Pharm, 2009b;377:185-98.
39. Zhang HX, Wang JX, Zhang ZB, Le Y, Shen ZG, Chen JF. Micronization of atorvastatin calcium by antisolvent precipitation process. Int J Pharm, 2009;374:106-13.
40. Zhang JY, Shen ZG, Zhong J, Hu TT, Chen JF, Ma ZQ, Yun Y. Preparation of amorphous cefuroxime axetil nanoparticles by controlled precipitation method without surfactants. Int J Pharm, 2006;323:153-60.